Optimization of the Ocular Surface Prior to Cataract Surgery Using PROKERA

Jeff Wongskhaluang43 enrolled

Overview

The purpose of the study is to assess whether PROKERA can sufficiently stabilize the ocular surface prior to cataract surgery and improve post operative outcomes patients with moderate to severe dry disease.

Amniotic membrane has been used to treat many ocular diseases and repair ocular surface damage. PROKERA contains amniotic membrane fastened between a ring system and can be worn in the eye like a contact lens. PROKERA is a medical device that was cleared by the United States Food and Drug Administration (FDA) in 2003. Cataract surgery is the most common eye surgery done in the United States. Prior to cataract surgery, machines scan the eyes to calculate which implant is needed at the time of cataract surgery. When a patient has dry eyes, the machines may have inaccurate measurements. The purpose of the study is to assess whether PROKERA can sufficiently stabilize the ocular surface prior to cataract surgery and improve post operative outcomes patients with moderate to severe dry disease. There will be a maximum of 64 eyes of individuals age 18 and older in the study enrolled at one study site. Each subject will have both eyes evaluated for the study. Prior to cataract surgery, patients enrolled in the study will have PROKERA device inserted on the surface of the eye. The subject will then come back after about five days to remove the PROKERA device and follow up again in one week and two weeks after the removal of the PROKERA device. During both of the follow up visits, the study doctor will grade symptoms based on a questionnaire, examine eyes, take pictures, and grade the severity of the dry eye disease to determine any changes from the baseline testing. At the two week visit, cataract surgery will be scheduled, which will be within one to two weeks time. After surgery, a one month postoperative visit will occur, where the same examination procedures are performed as the previous follow up visits.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Cataract Dry Eye Syndromes Cataract Senile Dry Eye

Interventions

PROKERADEVICE

Amniotic membrane is the sac that encloses the baby during pregnancy. Amniotic membrane has been used to treat many ocular (eye) diseases and repair ocular surface damage. PROKERA contains amniotic membrane fastened between a ring system and can be worn in the eye like a contact lens. PROKERA is a medical device that was cleared by the United States food and drug administration (FDA) in 2003.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. ≥ 18 years of age and plan to undergo cataract surgery 2. Prior use of DED/keratitis conservative treatments (artificial tears, ointment, Xiidra®, Restasis, warm compresses, etc.) within 30 days 3. Moderate to severe DED/keratitis (SPEED score ≥ 10) 4. Total cornea fluorescein staining score ≥ 4 (NEI scale) 5. Topographic changes such as irregularity, dropout, and higher order aberrations (HOAs; RMS \> 0.4) as determined by the investigator 6. Distorted keratometry mires or inconsistent biometry between 2 consecutive readings (30s apart) as determined by the investigator Exclusion Criteria: 7. Use of soft contacts lens, bandage contact lens, or scleral lens within 7 days 8. Ocular surgery within 3 months 9. History of refractive surgery (LASIK, keratectomy, radial keratotomy, etc.) 10. History of clinically significant ocular trauma 11. Significant posterior corneal astigmatism (≥ 0.75 D) 12. History of herpetic keratitis 13. Ongoing ocular or systemic infection 14. Visually significant retinal pathology 15. Clinically significant findings observed at screening, including lid abnormalities, epithelial basement membrane dystrophy, Salzmann's nodular degeneration, subclinical or clinical keratoconus (defined as KISA% index \> 6019), ectasia (Belin/Ambrosio enhanced ectasia display final 'D' index \> 2.6920), Fuchs' endothelial corneal dystrophy (Using the Classification by Sun et al21), etc. 16. Short eyes (axial length \< 22 mm22, 23) 17. High myopia (axial length ≥ 26 mm)22, 24 18. Eyes with glaucoma drainage devices or filtering bleb 19. Patients with a history of drug reactions to Ciprofloxacin, Amphotericin B, Glycerol, and/or DMEM. 20. Patient cannot close the eyelid, has an incomplete blink, or demonstrates any other signs of exposure that cannot be addressed by the investigator 21. Pregnancy or subject expecting to be pregnant 22. Use of additional eye medications (i.e. glaucoma eye drops, anti-histamines, etc)

Locations (1)

Grin Eye Care

Olathe, Kansas, United States

Outcomes

Primary Outcomes

Percentage to achieve emmetropia

Defined as spherical equivalent -0.5D to +0.5D and \<1.0D astigmatism before and after treatment

Time frame: 2-3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.